Cancer nanomedicine: a review of nano-therapeutics and challenges ahead

Active and passive mechanisms. Since FDA approval for Doxil®, several nano-therapeutics have been developed, and a few have received approval for use in cancer treatment. Along with liposomes, solid lipid nanoparticles, polymeric nanoparticles, and nanoemulsions, even newer techniques involving extracellular vesicles (EVs) and thermal nanomaterials are now being researched and implemented in practice. This review highlights the evolution and current status of cancer therapy, with a focus on clinical/pre-clinical nanomedicine cancer studies. Insight is also provided into the prospects in this regard.

• DO
  Department of Science and Technology, Ministry of Science and Technology, India
• II
  Indian Institute of Technology Madras
• VU
  VIT University
• SA
  Science and Engineering Research Board